B

Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315

Watchlist Manager
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Watchlist
Price: 8.25 HKD -2.02% Market Closed
Market Cap: 3.3B HKD
Have any thoughts about
Biocytogen Pharmaceuticals Beijing Co Ltd?
Write Note

Biocytogen Pharmaceuticals Beijing Co Ltd
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biocytogen Pharmaceuticals Beijing Co Ltd
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
B
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Accounts Payable
ÂĄ175.2m
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Accounts Payable
ÂĄ3.7B
CAGR 3-Years
20%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Accounts Payable
ÂĄ220.6m
CAGR 3-Years
-7%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Accounts Payable
ÂĄ299.9m
CAGR 3-Years
39%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Accounts Payable
ÂĄ16.3B
CAGR 3-Years
23%
CAGR 5-Years
42%
CAGR 10-Years
91%
Imeik Technology Development Co Ltd
SZSE:300896
Accounts Payable
ÂĄ44.7m
CAGR 3-Years
113%
CAGR 5-Years
17%
CAGR 10-Years
N/A
No Stocks Found

Biocytogen Pharmaceuticals Beijing Co Ltd
Glance View

Market Cap
3.3B HKD
Industry
Biotechnology

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. The company is headquartered in Beijing, Beijing. The company went IPO on 2022-09-01. The firm operates two business segments. The Drug Development Business segment is mainly engaged in the research and development of oncology and autoimmune disease treatments, as well as antibody development. The Preclinical Research Service segment is mainly engaged in gene editing, preclinical pharmacological efficacy evaluation and model animal sales.

Intrinsic Value
11.01 HKD
Undervaluation 25%
Intrinsic Value
Price
B

See Also

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Accounts Payable?
Accounts Payable
175.2m CNY

Based on the financial report for Dec 31, 2023, Biocytogen Pharmaceuticals Beijing Co Ltd's Accounts Payable amounts to 175.2m CNY.

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 3Y
26%

Over the last year, the Accounts Payable growth was 20%. The average annual Accounts Payable growth rates for Biocytogen Pharmaceuticals Beijing Co Ltd have been 26% over the past three years .

Back to Top